ClinicalTrials.gg
CompletedNCT06153693Updated May 1, 2026

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

A Phase 3 interventional study of Placebo and lorundrostat Dose 1 in Hypertension, sponsored by Mineralys Therapeutics Inc.. Completed at 184 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Mineralys Therapeutics Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,083
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.

Enrollment
144th of 1,779
1,083 · median 100
Started
2023
with 100 others
Phase 3
202 of 2,031
9 open now
Registered
1,736th of 2,031
by date

Among the 2,031 studies in Hypertension with a site in United States, this one is the 144th largest by enrollment of the 1,779 interventional ones that give a count, is one of 101 that started in 2023, is one of 202 in phase 3, and was the 1,736th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:

267 more — sign in →

All 272 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,031 studies in Hypertension with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.

Read the detailed description

This study is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications, one of which must be a thiazide or thiazide-like diuretic.

The study consists of a 2-week screening period with a 2-week single-blind run-in period followed by a 12-week randomized, double-blind, placebo-controlled, parallel arm period. Following the randomized period subjects will be offered an opportunity to participate in an open-label extension (OLE) study. Any subject electing to not participate in the OLE will undergo an end of study (EoS) visit, which will occur after end of treatment (EoT), to complete their participation in the study.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Blood pressure
  • Hypertension
  • Hypertensive
  • Resistant hypertension
  • Uncontrolled hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age at the time of signing the form (ICF)
  2. At Screening and Randomization: AOBP SBP of ≥135 and ≤180 mmHg plus AOBP DBP of ≥65 and ≤110 mmHg, or AOBP DBP of ≥90 and ≤110 mmHg
  3. Taking between 2 and 5 AHT medications,
  4. History of hypertension lasting at least 6 months prior to Screening
  5. (BMI) of ≥18 kg/m2 at Screening

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant, plan to become pregnant, or are breastfeeding
  2. Participation in a study involving any device or small-molecule drug within 4 weeks or 6 months for biologic (antibody) drugs prior to the Screening Visit
  3. \<45 mL/min/1.73m2 at Screening, calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
  4. Serum potassium >5.0 mmol/L at Screening or >4.8 mmol/L at Randomization
  5. Serum sodium \<135 mmol/L (corrected for hyperglycemia) at Screening.
  6. History of heart failure, myocardial infarction, stroke, or within 6 months prior to the Screening Visit.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,083 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo once daily (QD) for 12 weeks

    Drug: Placebo

  • Experimental
    Dose 1

    50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks

    Drug: lorundrostat Dose 1

  • Experimental
    Dose 2

    50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria

    Drug: lorundrostat Dose 2

Interventions

  • DrugPlacebo

    Placebo once daily (QD) for 12 weeks

  • Druglorundrostat Dose 1

    50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks

  • Druglorundrostat Dose 2

    50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria

06

What researchers measure

Primary outcomes

  1. Change from baseline in automated office BP (AOBP) SBP at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo

    Time frame: Week 6

Secondary outcomes

  1. Proportion of subjects with AOBP SBP <130 mmHg at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo

    Time frame: Week 6

  2. Change from baseline in AOBP SBP at Week 12 in subjects randomized to lorundrostat 50 mg QD with escalation to lorundrostat 100 mg QD compared to subjects randomized to placebo

    Time frame: Week 12

  3. Change from baseline in AOBP SBP at Week 6 in subjects with uncontrolled hypertension on 2 prescribed AHT medications

    Change from baseline in AOBP SBP at Week 6 in subjects with uncontrolled hypertension on 2 prescribed AHT medications randomized to lorundrostat 50 mg QD compared to subjects with uncontrolled hypertension on 2 prescribed AHT medications randomized to placebo

    Time frame: Week 6

  4. Change from baseline in AOBP SBP at Week 6 in subjects with uncontrolled hypertension on 3 or more prescribed AHT medications

    Change from baseline in AOBP SBP at Week 6 in subjects with uncontrolled hypertension on 3 or more prescribed AHT medications (resistant hypertension) randomized to lorundrostat 50 mg QD compared to subjects with uncontrolled hypertension on 3 or more prescribed AHT medications (resistant hypertension) randomized to placebo

    Time frame: Week 6

  5. Change from baseline in AOBP SBP at Week 6 by obesity status in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo

    Time frame: Week 6

  6. Change from baseline in AOBP SBP at Week 12 in subjects who were escalated to lorundrostat 100 mg QD at week 6 (within-subjects analysis)

    Time frame: Week 12

07

Study locations

184 sites
  • Advanced Cardiovascular, LLC - Alexander City Office
    Alexander City, Alabama 35010, United States
  • Central Research Associates, Inc
    Birmingham, Alabama 35205, United States
  • Cardiology, P.C.
    Birmingham, Alabama 35211-1309, United States
  • Synexus (Radiant Research, Inc) - Alabama - Simon Williamson Clinic Location
    Birmingham, Alabama 35211, United States
  • G & L Research LLC - Foley
    Foley, Alabama 36535, United States
  • Accel Research Sites (ARS) - Birmingham Clinical Research Unit
    Vestavia Hills, Alabama 35216, United States
  • Del Sol Research
    Tucson, Arizona 85715, United States
  • Entertainment Medical Group, Inc.
    Beverly Hills, California 90211, United States
  • Amicis Research Center - Granada Hills
    Granada Hills, California 91344, United States
  • Amicis Research Center - Northridge
    Granada Hills, California 91344, United States
  • Marvel Clinical Research, LLC
    Huntington Beach, California 92647, United States
  • Amicis Research Center
    Northridge, California 91324, United States
  • Pasadena Clinical Trials
    Pasadena, California 91101, United States
  • Empire Clinical Research (ECR)
    Pomona, California 91767, United States
  • Clinical Trials Research (CTR) - Sacramento
    Sacramento, California 95821, United States
  • North America Research Institute
    San Dimas, California 91773, United States
  • Amicis Research Center - Valencia
    Valencia, California 91355, United States
  • CMR of Greater New Haven
    Hamden, Connecticut 06517, United States
  • Chase Medical Research, LLC - Hamden
    Waterbury, Connecticut 06708-3346, United States
  • Indago Research and Health Center
    Hialeah, Florida 33012, United States
  • Clinical Neuroscience Solutions (CNS Healthcare) - Jacksonville
    Jacksonville, Florida 32256, United States
  • Nuovida Research Center Corp
    Miami, Florida 33175, United States
  • Clinical Neuroscience Solutions (CNS Healthcare) - Orlando Research Center
    Orlando, Florida 32801, United States
  • AES Orlando
    Orlando, Florida 32806, United States
  • Patron Medical - Andres Patron D.O. (Patron Ventures, LLC)
    Pembroke Pines, Florida 33026, United States
  • Pines Care Research Center, LLC
    Pembroke Pines, Florida 33026, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Clinical Research of West Florida (CRWF) - Clearwater
    Tampa, Florida 33606, United States
  • AES The Villages
    The Villages, Florida 32162, United States
  • Morehouse School of Medicine (MSM)
    Atlanta, Georgia 30310-1458, United States
  • ClinCept, LLC
    Columbus, Georgia 31904, United States
  • Accel Research Sites- Decatur
    Decatur, Georgia 30030, United States
  • Georgia Clinical Research Center, Inc
    Lawrenceville, Georgia 30044, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Rocky Mountain Diabetes Center
    Idaho Falls, Idaho 83404-7596, United States
  • Solaris Clinical Research (SCR)
    Meridian, Idaho 83616, United States
  • Synexus (Radiant Research, Inc) - Chicago
    Chicago, Illinois 60602, United States
  • Healthcare Research Network-Chicago, Illinois (Flossmoor) Location
    Flossmoor, Illinois 60422, United States
  • Koch Family Medicine, S.C.
    Morton, Illinois 61550, United States
  • Southern Illinois University School of Medicine - SIU Clinics - SIU Internal Medicine
    Springfield, Illinois 62702, United States
  • Investigators Research Group LLC
    Brownsburg, Indiana 46112, United States
  • Franciscan Physician Network
    Indianapolis, Indiana 46237-6345, United States
  • ASHA Clinical Research- Munster, LLC
    Munster, Indiana 46321, United States
  • Synexus (Radiant Research, Inc) - Evansville
    Newburgh, Indiana 47630, United States
  • Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
    Louisville, Kentucky 40213, United States
  • Tulane Doctors - Heart & Vascular - Metairie
    New Orleans, Louisiana 70112-2600, United States
  • The Alliance for Multispecialty Research LLC (AMR) - Louisiana
    New Orleans, Louisiana 70119, United States
  • Northwest Louisiana Nephrology, LLC - Shreveport
    Shreveport, Louisiana 71101, United States
  • Grace Research, LLC
    Shreveport, Louisiana 71115, United States
  • Boston Clinical Trials (BCT)
    Boston, Massachusetts 02131, United States
  • ActivMed Practices and Research
    Methuen, Massachusetts 01844, United States
  • Hattiesburg Clinic - Medisync Clinical Research
    Petal, Mississippi 39465, United States
  • Healthcare Research Network-Hazelwood
    Hazelwood, Missouri 63042, United States
  • Clinical Research Consultants (CRC) - Kansas City
    Kansas City, Missouri 64111, United States
  • Quality Clinical Research Inc. (QCR) - Omaha
    Omaha, Nebraska 68114, United States
  • Synexus (Radiant Research, Inc) - Nevada - Rita B. Chuang, MD
    Henderson, Nevada 89052, United States
  • Sierra Clinical Research-Las Vegas
    Las Vegas, Nevada 89106, United States
  • Renown Regional Medical Center (Washoe Medical Center)
    Reno, Nevada 89502, United States
  • Synexus (Radiant Research, Inc) - New York
    Jamaica, New York 11432, United States
  • North Shore Diabetes and Endocrine Associates (NSDEA) - New Hyde Park
    New Hyde Park, New York 11042-1214, United States
  • Columbia University
    New York, New York 10032-3725, United States
  • Randolph Health Internal Medicine/ Triad Internal Medicine
    Asheboro, North Carolina 272205, United States
  • East Carolina University (ECU) Physicians - East Carolina Heart Institute - East Carolina University Location
    Greenville, North Carolina 27834, United States
  • Physicians East, P.A. - Endocrinology
    Greenville, North Carolina 27834, United States
  • Carteret Medical Group - Morehead City
    Morehead City, North Carolina 28557, United States
  • Lucas Research, Inc. (Diabetes & Endocrinology Consultants PC) (DEC)
    New Bern, North Carolina 28562, United States
  • Diabetes & Endocrinology Associates of Stark County
    Canton, Ohio 44718, United States
  • Lynn Institute of Norman (LION Research)
    Norman, Oklahoma 73072, United States
  • Valley Kidney Specialists PC - Allentown Cedar Crest
    Bethlehem, Pennsylvania 18017, United States
  • Preferred Primary Care Physicians - Pleasant Hills - Curry Hollow Rd Location
    Pittsburgh, Pennsylvania 15236, United States
  • Preferred Primary Care Physicians (PPCP) - Uniontown - Jacob Murphy Lane Location
    Uniontown, Pennsylvania 15401, United States
  • Chattanooga Medical Research (CMR), LLC
    Chattanooga, Tennessee 37403, United States
  • The Alliance for Multispecialty Research LLC (AMR) - Knoxville (Volunteer Research Group)
    Knoxville, Tennessee 37920, United States
  • Clinical Neuroscience Solutions, Inc
    Memphis, Tennessee 38119, United States
  • Punzi Medical Center and Trinity Hypertension Research Institute
    Carrollton, Texas 75006, United States
  • AES Dallas Fort Worth
    Dallas, Texas 75234, United States
  • Synergy Groups Medical
    Houston, Texas 77036, United States
  • Juno Research, LLC
    Houston, Texas 77054, United States
  • Discovery Clinical Trials (DCT) - McAllen
    McAllen, Texas 78503, United States
  • Synergy Groups Medical - Missouri City
    Missouri City, Texas 35010, United States
  • North Texas Family Medicine (NTFM) - Plano Office
    Plano, Texas 75093, United States
  • Sun Research Institute (SRI) - San Antonio
    San Antonio, Texas 78215, United States
  • Discovery Clinical Trials (DCT) - San Antonio
    San Antonio, Texas 78258, United States
  • Global AES - Salt Lake City
    Salt Lake City, Utah 84106, United States
  • Velocity Clinical Research - Salt Lake City (Advanced Clinical Research)
    West Jordan, Utah 84088, United States
  • Burke Internal Medicine
    Burke, Virginia 22015, United States
  • Eastern VA Medical School
    Norfolk, Virginia 23501, United States
  • Castle Hill Medical Centre
    Castle Hill, New South Wales 2154, Australia
  • Renal Research - Gosford
    Gosford, New South Wales 2250, Australia
  • University of Newcastle - John Hunter Hospital (JHH)
    Waratah, New South Wales 2298, Australia
  • University of the Sunshine Coast - Clinical Trials Centre
    Sippy Downs, Queensland 4556, Australia
  • South Coast Renal
    Southport, Queensland 4215, Australia
  • AusTrials - Taringa
    Taringa, Queensland 4068, Australia
  • AusTrials - Wellers Hill
    Taringa, Queensland 4068, Australia
  • Fusion Clinical Research
    Adelaide, South Australia, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania 7000, Australia
  • Dobney Hypertension Centre/ Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • Austin Health - Heidelberg Repatriation Hospital
    Heidelberg Heights, 3081, Australia
  • AusTrials - Sunshine
    St Albans, VIC 3021, Australia
  • Medical Center New Polyclinic Gabrovo Ltd.
    Gabrovo, 5300, Bulgaria

Showing the first 100 of 184 sites across 13 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Saxena M, Laffin L, Borghi C, Fernandez Fernandez B, Ghali JK, Kopjar B, Polu K, Roger SD, Slingsby BT, Strutz F, Vogt L, Weir MR, Rodman D; Launch-HTN Investigators. Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial. JAMA. 2025 Aug 5;334(5):409-418. doi: 10.1001/jama.2025.9413. PubMed 40587141 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Dec 2024, 12 months.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 12 months is below that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2023
First posted
Dec 1, 2023
StartActual
Nov 22, 2023
Primary completionActual
Dec 10, 2024
CompletionActual
Jan 24, 2025
Results delay requested
Dec 8, 2025
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06153693
Lead sponsor
Mineralys Therapeutics Inc.
Responsible party
Sponsor
First posted
Dec 1, 2023
Start date
Nov 22, 2023
Primary completion
Dec 10, 2024
Completion
Jan 24, 2025
Last update
May 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion